Background Urinary tract infections are among the most common infections worldwide. Antibiotic resistance is an important medical problem because there is an increasing trend of antibiotic resistance worldwide making it harder to eliminate uropathogens. Antibiotic resistance shows a geographical variation. Hence, local studies are necessary to determine prevalence of uroptahogens among UTI patients. Thus, this study was conducted to determine prevalence of uropathogens among UTI patients and their antimicrobial susceptibility pattern from the data of 12 years period from 2010 to 2022 in Duhok Province, Kurdistan Region, Iraq Materials and methods This study was conducted by retrieving 12-year laboratory records between 2010 and 2022. data were collected from Azadi teaching hospital in Duhok city in Kurdistan region in northern Iraq. uropathogen species were identified by routine laboratory methods. Antimicrobial sensitivity testing was performed manually and by Vitek-2 automated susceptibility system. Results The results of gram-positive urine pathogens of 249 patients showed Staphylococcus haemolyticus (20.9%) was the most common isolated pathogen, followed by staphylococcus aureus (7.6%), Streptococcus Agalactiae (6.4%) and Enterococcus spp. (6%). S. haemolyticus had highest resistance to nitrofurantoin (61.5%) and lowest amikacin (34.3%). S. aureus showed highest resistance to penicillin 73.3% and highest sensitivity to amikacin (78.9%).in our study, Streptococcus agalactiae had the highest sensitivity to vancomycin (%87.5). 93.3% of enterococcus spp. were resistant to tetracycline. Conclusion UTIs are more common in female than in male and coagulase-negative Staph species are the most commonly isolated pathogens. This study found antimicrobial resistance to commonly prescribed antibiotics are high. Hence, an urgent plan to control antimicrobial resistance is necessary in our area.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the ethics committee at the University of Duhok, college of medicine, Kurdistan Region, Iraq.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript